Search results
Added:
5 months ago
Source:
Radcliffe CVRM
Obesity is a primary risk factor for dyslipidaemia and cardiovascular disease (CVD), but the mechanisms linking weight gain to lipid metabolism are not fully understood. A new study suggests that in a specific genetic form of obesity caused by melanocortin 4 receptor (MC4R) deficiency, individuals may have a more favourable cardiometabolic profile despite their higher body weight.¹This multi-part…
View more
AHA 24: The SELECT Trial
Added:
1 year ago
Video
Added:
8 months ago
Source:
Radcliffe CVRM
A prespecified secondary analysis of the EAST-AFNET 4 trial has found that the benefits of an early rhythm control strategy for patients with recently diagnosed atrial fibrillation (AF) are maintained regardless of whether patients have obesity or diabetes.¹ These findings suggest that clinicians should not withhold this therapeutic approach based on these common metabolic comorbidities.The…
View more
Added:
1 year ago
Source:
Radcliffe CVRM
AUTHOR: Sean DelaneyWednesday 5th February, 2025 - Non-alcoholic fatty liver disease (NAFLD) is a global health challenge traditionally linked to obesity. However, recent research highlights its increasing prevalence among non-obese individuals, particularly young adults. A recently published prospective cohort study in Digestive Diseases and Sciences examines the relationship between serum uric…
View more
Added:
1 year ago
Source:
European Renal Association
The SELECT Trial has revealed the potential of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in combating kidney function decline among individuals with overweight or obesity and established cardiovascular disease but without diabetes.1Unveiling the results today at the 61st ERA Congress, researchers presented the impressive secondary analysis from the SELECT (Semaglutide…
View more
Start date:
Mar 04, 2025
End date:
Mar 05, 2025
Obesity at the Limits 2025 is a new major event running five international meetings across the globe on March 4th to March 5th 2025, coinciding with World Obesity Day. The event will include a range of live speakers and streamed presentations from select global experts meeting from Europe, Africa / the Middle East, Asia Pacific, North America, and South America.
View more
Added:
1 year ago
Source:
Radcliffe Cardiology
AUTHOR: David RamseyAmerican Diabetes Scientific Sessions, 23 June 2024 – The data from three studies investigating glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1/GIP (glucose-dependent insulinotropic polypeptide) receptor agonists in patients with obesity was recently presented at a late-breaking session at the American Diabetes Association’s 84th Scientific Sessions in Orlando…
View more
Added:
8 months ago
Source:
Radcliffe CVRM
A new multi-ancestry polygenic score (PGS) for body mass index (BMI), developed using genetic data from over 5.1 million people, substantially improves the prediction of obesity across the life course compared to previous scores.¹ The research, which drew data from the GIANT consortium and 23andMe, demonstrates particular value in predicting obesity risk from early childhood and in understanding…
View more
Added:
4 months ago
Source:
Radcliffe CVRM
A new study has found that orforglipron, a novel, once-daily oral glucagon-like peptide-1 (GLP-1) receptor agonist, leads to significant weight loss in adults with obesity or overweight and type 2 diabetes (T2D). The findings come from the phase 3 ATTAIN-2 trial.¹Orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist, distinguishing it from existing injectable peptide-based…
View more
Metabolic Surgery Superior to GLP-1 RAs for Long-Term Outcomes in Patients with Diabetes and Obesity
Added:
7 months ago
Source:
Radcliffe CVRM
News